Skip to content
MARKETS / NASDAQ / HYPR
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Hyperfine, Inc. HYPR

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.6M
▲ 5.2% YoY
$-35.6M
$-29.1M
In brief

What this company does

As of February 15, 2026, we had 102 employees, all of whom were full-time employees and of whom 24 work in sales, marketing, and commercial support, 56 work in research, development, clinical, technical assistance, supply chain, operations and logistics and 22 work in general and administrative capacities. None of our employees are represented by a labor union or are subject to We believe our market opportunity is significant across the multiple sites of care where the Swoop® system brings clinical and economic value.

Written from the business description in Hyperfine, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.

Growth
USD 13.6M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.6 · Net income -35.6
5.0M10.0M-25.0M-50.0M202020212022202320242025
Compound annual growth
+25.8%
+115.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +115.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−262 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -273.4% · Net -262.3%
-2000%-4000%-6000%202020212022202320242025
ROE
FY2025 · ROE -79.0%
-50%-100%202020212022202320242025

Each USD of equity lost 79 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -29.1
-25.0M-50.0M202020212022202320242025

Total assetsUSD 55.3M
EquityUSD 41.0M
CashUSD 35.1M
Current ratio4.34×

Equity funds 74% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.1−0.1−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.1−0.0
Income tax $B0.00.00.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.1−0.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.0−0.0
EPS, diluted $−0.43−0.56−0.62−1.04−17.57−15.38
Dividend / sh $······
Payout %······
ROE %−79.0−61.0−42.5−28.5−103.6·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image